multiple myeloma
Karolinska Institutet, Cellply Partner to Improve Knowledge of NK Cell Therapies in Multiple Myeloma
Researchers will use Cellply's VivaCyte platform to conduct single-cell analyses of NK cells and evaluate their ability to treat the bone marrow cancer.
The firm's LLM-based platform abstracted complex information from medical charts with up to 100 percent accuracy in a pilot study of breast cancer patients.
Legend, Janssen Will Invest $150M to Expand Carvykti Manufacturing in Europe
The firms expect that by expanding manufacturing capacity they can double the sales volume of Carvykti from 10,000 doses in 2025 to 20,000 doses in 2027.
Sales of the firm's cell therapy franchise grew modestly in the fourth quarter amid competing product launches and overall slow uptake within the class.
J&J Reports Strong Uptake of Carvykti and Rybrevant in Q4
The company's multiple myeloma franchise, which includes Carvykti, stands to contribute significantly to its growth in 2025.